US 12,103,977 B2
Trispecific antibody targeting CD79b, CD20, and CD3
Rajkumar Ganesan, Blue Bell, PA (US); Anna Kuchnio, Edegem (BE); Cassandra L. Lowenstein, Ambler, PA (US); Ulrike Philippar, Antwerp (BE); Sanjaya Singh, Blue Bell, PA (US); Nele Vloemans, Oostmalle (BE); and Danlin Yang, Philadelphia, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Mar. 23, 2022, as Appl. No. 17/702,282.
Claims priority of provisional application 63/286,309, filed on Dec. 6, 2021.
Claims priority of provisional application 63/165,501, filed on Mar. 24, 2021.
Prior Publication US 2022/0315663 A1, Oct. 6, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 35 Claims
OG exemplary drawing
 
1. A trispecific antibody, or a trispecific binding fragment thereof, comprising:
(a) a first antigen-binding arm comprising a first heavy chain variable domain (VH1) and a first light chain variable domain (VL1),
wherein the VH1 and VL1 comprise the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of:
a) SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively;
b) SEQ ID NOs: 13, 8, 9, 10, 11 and 12, respectively;
c) SEQ ID NOs: 7, 8, 9, 10, 11 and 12, respectively;
d) SEQ ID NOs: 14, 15, 16, 17, 5 and 6, respectively;
e) SEQ ID NOs: 18, 8, 19, 20, 21 and 12, respectively;
f) SEQ ID NOs: 22, 23, 24, 25, 5 and 6, respectively;
g) SEQ ID NOs: 22, 26, 27, 28, 5 and 29, respectively; or
h) SEQ ID NOs: 30, 31, 32, 33, 5 and 6, respectively;
(b) a second antigen-binding arm comprising a second heavy chain variable domain (VH2) and a second light chain variable domain (VL2),
wherein the VH2 and VL2 comprise the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of:
a) SEQ ID NOs: 76, 77, 78, 79, 80 and 81, respectively;
b) SEQ ID NOs: 76, 77, 75, 79, 80 and 81, respectively;
c) SEQ ID NOs: 76, 77, 82, 79, 80 and 81, respectively; or
d) SEQ ID NOs: 83, 84, 85, 86, 87 and 88, respectively;
(c) a third antigen-binding arm comprising a third heavy chain variable domain (VH3) and a third light chain variable domain (VL3),
wherein the VH3 and VL3 comprise the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of:
a) SEQ ID NOs: 115, 116, 117, 118, 119 and 120, respectively;
b) SEQ ID NOs: 121, 122, 123, 124, 119 and 125, respectively;
c) SEQ ID NOs: 115, 116, 95, 96, 119 and 125, respectively; or
d) SEQ ID NOs: 121, 116, 123, 124, 119 and 125, respectively,
wherein the first antigen-binding arm binds to an epitope on cluster of differentiation 79B protein (CD79b), the second antigen-binding arm binds to an epitope on cluster of differentiation 3 (CD3), and the third antigen-binding arm binds to an epitope on cluster of differentiation 20 (CD20).